Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort.

OBJECTIVE To evaluate the clinical presentation and long-term outcome of a vasculitis centre cohort of patients with microscopic polyangiitis (MPA) with respect to organ manifestations, treatment, chronic damage and mortality. METHODS We performed a retrospective chart review at our vasculitis referral centre. MPA patients admitted between 1991 and 2013 classified by a modified European Medicines Agency algorithm were diagnosed and treated according to a standardized interdisciplinary approach. RESULTS Comprehensive data from standardized interdisciplinary workups was available for 144 patients (median follow-up 72 months). The overall standardized mortality ratio was 1.40 (95% CI 0.91, 2.07; P = 0.13). We observed a higher mortality [hazard ratio (HR) 4.04 (95% CI 1.21, 13.45), P = 0.02] in 17 patients with MPA-associated fibrosing interstitial lung disease (ILD) and 56 patients with peripheral nervous system involvement [HR 5.26 (95% CI 1.10, 25.14), P = 0.04] at disease onset. One hundred and fifteen patients (79.9%) responded to the initial treatment. Sixty-one (42.3%) achieved complete remission and 54 (37.5%) achieved partial remission. Twenty (13.9%) showed a refractory disease course. CONCLUSION MPA patients at our tertiary rheumatology referral centre seemed to have a less severe phenotype resulting in a less severe disease course and better outcome than reported in other cohorts. Fibrosing ILD was significantly associated with mortality in this cohort.

[1]  F. Caputo,et al.  Microscopic polyangiitis associated with pulmonary fibrosis , 2015, Clinical Rheumatology.

[2]  Shigao Huang,et al.  Cord Blood-Derived Cytokine-Induced Killer Cellular Therapy Plus Radiation Therapy for Esophageal Cancer , 2014, Medicine.

[3]  S. Kikuchi,et al.  Retrospective analysis of factors predicting end-stage renal failure or death in patients with microscopic polyangiitis with mainly renal involvement , 2014, Clinical and Experimental Nephrology.

[4]  Kaifeng Xu,et al.  A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China , 2014, BMC Pulmonary Medicine.

[5]  栄一 末松.  血管炎の新分類2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides , 2013 .

[6]  H. Makino,et al.  Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan , 2013, The Journal of Rheumatology.

[7]  Y. Kondoh,et al.  Interstitial pneumonia associated with MPO-ANCA: clinicopathological features of nine patients. , 2012, Respiratory medicine.

[8]  H. Makino,et al.  Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan , 2012, Clinical and Experimental Nephrology.

[9]  N. Arden,et al.  Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. , 2011, Rheumatology.

[10]  P. Ind,et al.  Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. , 2011, Rheumatology.

[11]  J. del Pino-Montes,et al.  Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. , 2011, Rheumatology.

[12]  D. Jayne,et al.  Management of alveolar hemorrhage in lung vasculitides. , 2011, Seminars in respiratory and critical care medicine.

[13]  P. Höglund,et al.  Long-term patient survival in ANCA-associated vasculitis , 2010, Annals of the rheumatic diseases.

[14]  L. Jacobsson,et al.  Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. , 2009, Rheumatology.

[15]  M. Kokosi,et al.  Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis , 2009, European Respiratory Journal.

[16]  P. Nightingale,et al.  Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis , 2009, Annals of the rheumatic diseases.

[17]  V. Tesar,et al.  Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis , 2009, Annals of Internal Medicine.

[18]  Z. Amoura,et al.  Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature , 2008, Annals of the rheumatic diseases.

[19]  V. Cottin,et al.  ANCA-associated lung fibrosis: analysis of 17 patients. , 2008, Respiratory medicine.

[20]  H. Raspe,et al.  EULAR recommendations for the management of primary small and medium vessel vasculitis , 2008, Annals of the Rheumatic Diseases.

[21]  H. Raspe,et al.  Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force , 2007, Annals of the rheumatic diseases.

[22]  L. Cattaneo,et al.  Peripheral neuropathy in Wegener’s granulomatosis, Churg–Strauss syndrome and microscopic polyangiitis , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[23]  H. Raspe,et al.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis , 2006, Annals of the rheumatic diseases.

[24]  D. Scott,et al.  Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies , 2006, Annals of the rheumatic diseases.

[25]  U. Maggiore,et al.  Outcome and prognostic factors during the course of primary small-vessel vasculitides. , 2006, The Journal of rheumatology.

[26]  V. Tesar,et al.  Long-Term Outcome of Patients with Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Renal Involvement , 2005, Kidney and Blood Pressure Research.

[27]  D. Scott,et al.  Primary systemic vasculitis: clinical features and mortality. , 2005, QJM : monthly journal of the Association of Physicians.

[28]  G. Sobue,et al.  Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. , 2002, The Journal of rheumatology.

[29]  M. Heller,et al.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. , 2000, Arthritis and rheumatism.

[30]  J. Amouroux,et al.  Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. , 1999, Arthritis and rheumatism.

[31]  J. Ranstam,et al.  Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. , 1998, Journal of the American Society of Nephrology : JASN.

[32]  C. Gordon,et al.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.

[33]  R. Moots,et al.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.

[34]  Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis: A Series of 49 Patients and Review of the Literature: Erratum. , 2015, Medicine.

[35]  H. Doll,et al.  Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. , 2015, Annals of the rheumatic diseases.

[36]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[37]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[38]  E. Daugas,et al.  Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors. , 2012, Clinical and experimental rheumatology.

[39]  M. Heller,et al.  Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. , 2011, Arthritis and rheumatism.

[40]  安藤 ゆみ子.  Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease : CT findings in 51 patients , 2007 .

[41]  K. De Groot,et al.  Development and validation of a disease extent index for Wegener's granulomatosis. , 2001, Clinical nephrology.

[42]  J. Nossent,et al.  Fibrosing alveolitis predating microscopic polyangiitis. , 1999, Scandinavian journal of rheumatology.

[43]  R. Falk,et al.  Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.

[44]  R. Falk,et al.  Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.